IP Library › Granted Patent US 7,795,032
Granted Patent B2
US 7,795,032 · App. 10/713,008 · Granted Sep 14, 2010

Methods for proliferating cardiomyocytes and recombinant vectors therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,032
App. No.
10/713,008
Granted
Sep 14, 2010
Kind
B2
Abstract

Terminal differentiated cells are proliferated by introducing a cyclin and a cyclin dependent kinase into the nucleus of terminal differentiated cells, and then cultivating or holding the cells. A method for proliferating terminal differentiated cells comprising adding a nucleotide sequence coding for a nuclear localization signal to at least one of a cyclin gene and a cyclin dependent kinase gene, and introducing each of the genes to terminal differentiated cells in vitro, and then cultivating the cells, or introducing each of the genes directly to terminal differentiated cells in vivo is provided. The cyclin is a cyclin that can activate CDK4 or CDK6, and the cyclin dependent kinase is a cyclin dependent kinase that is activated by D-type cyclin. The invention also provides a recombinant vector used for such a method or a pharmaceutical composition comprising the vector.

Claims (33)

1. A method for proliferating cardiomyocytes comprising: introducing nucleotide sequences coding for a D-type cyclin gene and a cyclin dependent kinase gene directly into the cardiomyocytes using a viral vector and expressing said nucleotide sequences in said cardiomyocytes,

wherein said cyclin gene is a gene coding for cyclin D1, D2 or D3,

wherein said cyclin dependent kinase gene is a gene coding for CDK4 or CDK6, and

wherein a nucleotide sequence coding for a nuclear localization signal is attached to at least one of said cyclin gene or said cyclin dependent kinase gene.

2. A method for proliferating cardiomyocytes comprising: introducing nucleotide sequences coding for a D-type cyclin gene and a cyclin dependent kinase gene into cardiomyocytes in vitro using a viral vector and expressing said nucleotide sequences in said cardiomyocytes, and then cultivating said cardiomyocytes, or introducing each of said genes directly to cardiomyocytes in vivo using a viral vector and expressing said genes in said cardiomyocytes,

wherein said cyclin gene is a gene coding for cyclin D1, D2 or D3,

wherein said cyclin dependent kinase gene a gene coding for is CDK4 or CDK6, and

wherein a nucleotide sequence coding for a nuclear localization signal is attached to at least one of said cyclin gene or said cyclin dependent kinase gene.

3. The method of claim 2 , wherein said viral vector is an adenovirus vector.

4. The method of claim 2 , wherein said genes comprising said nucleotide sequences are introduced to the cardiomyocytes in vitro, and cultivating said cardiomyocytes.

5. The method of claim 2 , wherein said genes comprising said nucleotide sequences are introduced to the cardiomyocytes in vivo.

6. The method of claim 1 or 2 , wherein said cyclin activates CDK4.

7. The method of claim 1 or 2 , wherein said cyclin activates CDK6.

8. The method of claim 2 , wherein said cyclin is D1.

9. The method of claim 1 , wherein the cyclin is D2 or D3.

10. The method of claim 2 , wherein the cyclin is D2 or D3.

11. The method of claim 1 , wherein the cyclin dependent kinase is CDK4.

12. The method of claim 1 , wherein the D-type cyclin is D1.

13. The method of claim 4 , wherein the cyclin dependent kinase is CDK4.

14. The method of claim 4 , wherein the D-type cyclin is D1.

15. The method of claim 4 , wherein the cyclin dependent kinase is CDK4 and the D-type cyclin is D1.

16. The method of claim 5 , wherein the cyclin dependent kinase is CDK4.

17. The method of claim 5 , wherein the D-type cyclin is D1.

18. The method of claim 5 , wherein the cyclin dependent kinase is CDK4 and the D-type cyclin is D1.

19. A method for proliferating cardiomyocytes in vitro comprising: introducing nucleotide sequences coding for a D-type cyclin and a recombinant cyclin dependent kinase gene directly into the cardiomyocytes using a viral vector and expressing said nucleotide sequences in said cardiomyocytes, and cultivating or holding said cardiomyocytes,

wherein said cyclin gene is a gene coding for cyclin D1, D2 or D3,

wherein said cyclin dependent kinase gene is a gene coding for CDK4 or CDK6, and

wherein a nucleotide sequence coding for a nuclear localization signal is attached to at least one of said cyclin gene or said cyclin dependent kinase gene.

20. A method for proliferating cardiomyocytes in vivo comprising: introducing nucleotide sequences coding for a D-type cyclin gene and a cyclin dependent kinase gene directly to cardiomyocytes in vivo using a viral vector and expressing said nucleotide sequences in said cardiomyocytes,

wherein said cyclin is cyclin D1, D2 or D3,

wherein said cyclin dependent kinase is CDK4 or CDK6, and

wherein a nucleotide sequence coding for a nuclear localization signal is attached to at least one of said cyclin gene or said cyclin dependent kinase gene.

21. The method of claim 1 , wherein said viral vector is an adenovirus vector.

Priority Claims (1)
JP 2001-148266 · May 17, 2001 · national
Continuity (2)
Continuation PCTJP010820800 · Sep 21, 2001
Related Publication 20050208659A1 · Sep 22, 2005